Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

The saphenous nerve in foot and ankle surgery: its variable anatomy and relevance.

Marsland D, Dray A, Little NJ, Solan MC.

Foot Ankle Surg. 2013 Jun;19(2):76-9. doi: 10.1016/j.fas.2012.10.007. Epub 2012 Dec 27.

PMID:
23548446
2.

An incidence estimation model for multi-stage diseases with differential mortality.

Dray A, Williams T.

Stat Med. 2012 Nov 30;31(27):3379-92. doi: 10.1002/sim.5423. Epub 2012 Aug 1.

PMID:
22855255
3.

Are drug detection dogs and mass-media campaigns likely to be effective policy responses to psychostimulant use and related harm? Results from an agent-based simulation model.

Dray A, Perez P, Moore D, Dietze P, Bammer G, Jenkinson R, Siokou C, Green R, Hudson SL, Maher L.

Int J Drug Policy. 2012 Mar;23(2):148-53. doi: 10.1016/j.drugpo.2011.05.018. Epub 2011 Jul 13.

PMID:
21742481
4.

SimAmph: an agent-based simulation model for exploring the use of psychostimulants and related harm amongst young Australians.

Perez P, Dray A, Moore D, Dietze P, Bammer G, Jenkinson R, Siokou C, Green R, Hudson SL, Maher L.

Int J Drug Policy. 2012 Jan;23(1):62-71. doi: 10.1016/j.drugpo.2011.05.017. Epub 2011 Jun 29.

PMID:
21715152
5.

Estimating incidence of vision-reducing cataract in Africa: a new model with implications for program targets.

Lewallen S, Williams TD, Dray A, Stock BC, Mathenge W, Oye J, Nkurikiye J, Kimani K, Müller A, Courtright P.

Arch Ophthalmol. 2010 Dec;128(12):1584-9. doi: 10.1001/archophthalmol.2010.307.

PMID:
21149783
6.

Evaluating participatory modeling: developing a framework for cross-case analysis.

Jones NA, Perez P, Measham TG, Kelly GJ, d'Aquino P, Daniell KA, Dray A, Ferrand N.

Environ Manage. 2009 Dec;44(6):1180-95. doi: 10.1007/s00267-009-9391-8. Epub 2009 Oct 22.

PMID:
19847478
7.

Extending drug ethno-epidemiology using agent-based modelling.

Moore D, Dray A, Green R, Hudson SL, Jenkinson R, Siokou C, Perez P, Bammer G, Maher L, Dietze P.

Addiction. 2009 Dec;104(12):1991-7. doi: 10.1111/j.1360-0443.2009.02709.x. Epub 2009 Oct 5.

PMID:
19804460
8.

New horizons in pharmacologic treatment for rheumatic disease pain.

Dray A.

Rheum Dis Clin North Am. 2008 May;34(2):481-505. doi: 10.1016/j.rdc.2008.04.005.

PMID:
18638688
9.

Neuropathic pain: emerging treatments.

Dray A.

Br J Anaesth. 2008 Jul;101(1):48-58. doi: 10.1093/bja/aen107. Epub 2008 May 28. Review.

10.

Osteoarthritic pain: a review of current, theoretical and emerging therapeutics.

Read SJ, Dray A.

Expert Opin Investig Drugs. 2008 May;17(5):619-40. doi: 10.1517/13543784.17.5.619 . Review.

PMID:
18447590
11.

Arthritis and pain. Future targets to control osteoarthritis pain.

Dray A, Read SJ.

Arthritis Res Ther. 2007;9(3):212. Review.

12.

Novel molecular targets in pain control.

Dray A.

Curr Opin Anaesthesiol. 2003 Oct;16(5):521-5.

PMID:
17021506
13.

Future pharmacologic management of neuropathic pain.

Dray A.

J Orofac Pain. 2004 Fall;18(4):381-5.

PMID:
15636024
14.

Novel G protein-coupled receptors as pain targets.

Ahmad S, Dray A.

Curr Opin Investig Drugs. 2004 Jan;5(1):67-70. Review.

PMID:
14983976
15.

A pro-nociceptive role of neuromedin U in adult mice.

Cao CQ, Yu XH, Dray A, Filosa A, Perkins MN.

Pain. 2003 Aug;104(3):609-16.

PMID:
12927633
16.

Intrathecal nerve growth factor restores opioid effectiveness in an animal model of neuropathic pain.

Cahill CM, Dray A, Coderre TJ.

Neuropharmacology. 2003 Sep;45(4):543-52.

17.

Pro-nociceptive effects of neuromedin U in rat.

Yu XH, Cao CQ, Mennicken F, Puma C, Dray A, O'Donnell D, Ahmad S, Perkins M.

Neuroscience. 2003;120(2):467-74.

PMID:
12890516
18.
19.

Antisense oligonucleotide knockdown of mGluR1 alleviates hyperalgesia and allodynia associated with chronic inflammation.

Fundytus ME, Osborne MG, Henry JL, Coderre TJ, Dray A.

Pharmacol Biochem Behav. 2002 Sep;73(2):401-10.

PMID:
12117595
20.

Proenkephalin A gene products activate a new family of sensory neuron--specific GPCRs.

Lembo PM, Grazzini E, Groblewski T, O'Donnell D, Roy MO, Zhang J, Hoffert C, Cao J, Schmidt R, Pelletier M, Labarre M, Gosselin M, Fortin Y, Banville D, Shen SH, Ström P, Payza K, Dray A, Walker P, Ahmad S.

Nat Neurosci. 2002 Mar;5(3):201-9.

PMID:
11850634
21.
22.
23.

Knockdown of spinal metabotropic glutamate receptor 1 (mGluR(1)) alleviates pain and restores opioid efficacy after nerve injury in rats.

Fundytus ME, Yashpal K, Chabot JG, Osborne MG, Lefebvre CD, Dray A, Henry JL, Coderre TJ.

Br J Pharmacol. 2001 Jan;132(1):354-67.

24.
25.

Ions in the fire: recent ion-channel research and approaches to pain therapy.

Eglen RM, Hunter JC, Dray A.

Trends Pharmacol Sci. 1999 Aug;20(8):337-42. Review.

PMID:
10431213
26.

Priming enhances endotoxin-induced thermal hyperalgesia and mechanical allodynia in rats.

Cahill CM, Dray A, Coderre TJ.

Brain Res. 1998 Oct 12;808(1):13-22.

PMID:
9795108
27.

The how and why of chronic pain states and the what of new analgesia therapies.

Dray A, Rang H.

Trends Neurosci. 1998 Aug;21(8):315-7. No abstract available.

PMID:
9720594
28.

In vivo antinociceptive activity of anti-rat mGluR1 and mGluR5 antibodies in rats.

Fundytus ME, Fisher K, Dray A, Henry JL, Coderre TJ.

Neuroreport. 1998 Mar 9;9(4):731-5.

PMID:
9559947
29.

Kinins and their receptors in hyperalgesia.

Dray A.

Can J Physiol Pharmacol. 1997 Jun;75(6):704-12. Review.

PMID:
9276152
30.

Analogues of capsaicin with agonist activity as novel analgesic agents: structure-activity studies. 4. Potent, orally active analgesics.

Wrigglesworth R, Walpole CS, Bevan S, Campbell EA, Dray A, Hughes GA, James I, Masdin KJ, Winter J.

J Med Chem. 1996 Dec 6;39(25):4942-51.

PMID:
8960554
31.

Novel pharmacological strategies for analgesia.

Perkins M, Dray A.

Ann Rheum Dis. 1996 Oct;55(10):715-22. Review. No abstract available.

32.

Metabotropic glutamate receptor activation contributes to nociceptive reflex activity in the rat spinal cord in vitro.

Boxall SJ, Thompson SW, Dray A, Dickenson AH, Urban L.

Neuroscience. 1996 Sep;74(1):13-20.

PMID:
8843073
33.

Commissioning. Life preservers.

Greagsby P, Dray A, Milner P.

Health Serv J. 1996 Jul 4;106(5510):28-9. No abstract available.

PMID:
10159400
36.
38.

Neurogenic mechanisms and neuropeptides in chronic pain.

Dray A.

Prog Brain Res. 1996;110:85-94. Review. No abstract available.

PMID:
9000717
39.

New pharmacological strategies for pain relief.

Dray A, Urban L.

Annu Rev Pharmacol Toxicol. 1996;36:253-80. Review.

PMID:
8725390
40.

Possible branching of myelinated primary afferent fibres in the dorsal root of the rat.

Nagy I, Dray A, Urban L.

Brain Res. 1995 Dec 12;703(1-2):223-6.

PMID:
8719637
42.
44.

Inflammatory mediators of pain.

Dray A.

Br J Anaesth. 1995 Aug;75(2):125-31. Review.

45.

Bradykinin depolarises the rat isolated superior cervical ganglion via B2 receptor activation.

Babbedge R, Dray A, Urban L.

Neurosci Lett. 1995 Jul 7;193(3):161-4.

PMID:
7478173
46.

No evidence for contribution of nitric oxide to spinal reflex activity in the rat spinal cord in vitro.

Thompson SW, Babbedge R, Levers T, Dray A, Urban L.

Neurosci Lett. 1995 Mar 24;188(2):121-4.

PMID:
7792055
47.

Peptidergic afferents: physiological aspects.

Urban L, Thompson SW, Fox AJ, Jeftinija S, Dray A.

Prog Brain Res. 1995;104:255-69. Review. No abstract available.

PMID:
8552772
48.

Kinins and kinin receptors in the nervous system.

Walker K, Perkins M, Dray A.

Neurochem Int. 1995 Jan;26(1):1-16; discussion 17-26. Review.

PMID:
7787759
49.
50.

Regulation of bradykinin sensitivity in peripheral sensory fibres of the neonatal rat by nitric oxide and cyclic GMP.

Rueff A, Patel IA, Urban L, Dray A.

Neuropharmacology. 1994 Oct;33(10):1139-45.

PMID:
7862249

Supplemental Content

Support Center